SRI and chronic myelogenous leukemia, BCR-ABL1 positive: Several previous studies have shown that co-treatment with ampelopsin and ondansetron enhanced the antiproliferative effect of adriamycin in adriamycin-resistant K562 CML cells by downregulating soluble resistance-related calcium-binding protein (SORCIN) [42].